3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Pain
10
Neoplasms
8
Cancer Pain
6
Pain, Postoperative
2
Pain, Intractable
2
Leukemia
2
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Thrombocythemia, Essential
1
Stomatitis
1
Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
1
Squamous Cell Carcinoma of Head and Neck
1
Spinal Surgery
1
Signs and Symptoms
1
Sezary Syndrome
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Postoperative Complications
1
Polycythemia Vera
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Pathologic Processes
1
Neurologic Manifestations
1
Neuralgia
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Interventions
Oxaliplatin
32
Fluorouracil
24
Gemcitabine
23
Leucovorin
19
Docetaxel
19
pembrolizumab
17
Capecitabine
15
Radiotherapy
14
Irinotecan
13
Cisplatin
11
Bevacizumab
11
Nivolumab
8
130-nm albumin-bound paclitaxel
8
Trastuzumab
7
Erlotinib Hydrochloride
7
Cyclophosphamide
7
Albumin-Bound Paclitaxel
7
Radiosurgery
6
Paclitaxel
6
Taxes
5
S 1 (combination)
5
Metformin
5
Carboplatin
5
Blood Specimen Collection
5
Sunitinib
4
Sorafenib
4
Pemetrexed
4
Esophagectomy
4
Chemoradiotherapy
4
Cetuximab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Adenocarcinoma
×
Methadone
×
Clear all
NCT05325164
2022-12-05
METHADOPT
Ottawa Hospital Research Institute
Phase 3
Withdrawn